BioManufacturing (BioMAN) Research Program
Challenge: Estimates indicate that the pharmaceutical industry could be wasting more than $50 billion a year in manufacturing costs. The CBI is evaluating the influence of science, technology, policy, and business dynamics on the future of biomanufacturing. The BioMAN research program focuses on developing new tools and technologies to influence this development in a way that positively impacts healthcare.
Approach: The CBI is establishing working groups across the value chain including manufacturers, vendors, the government, and academia to discuss the future of biomanufacturing and to define research and technology needs. BioMAN will provide a safe haven forum for participants to explore potential solution paths and discuss the impact of new technology developments. We will leverage MIT research in both engineering and science to gain insights into new technologies for bioprocessing, from miniaturized analyzers to microbioreactors to online monitoring tools. BioMAN will also draw on MIT’s expertise in business strategy, economic cost modeling, and system dynamics to develop tools that assess the strategic, business, and financial implications of new technologies.
BioMAN Projects
- Industry Needs Assessment: Identifying Critical Barriers in the Biomanufacturing Industry
- bioPAT Applied: Advancing Process Analytical Tools for Biomanufacturing
- BioMAN Working Group: Sensors for Bioprocessing-Exploring New Technologies for Online Measurements
- BioMAN Futures: Evaluating Drivers of Change and Future Scenarios for Biomanufacturing
BioMAN News
On January 28th 2008, The Center for Biomedical Innovation, together with the NIH, the FDA, and NIST, organized the special session entitled "A 10-year Vision of Biotechnology Manufacturing" at the annual meeting of the International Forum for Process Analytical Chemistry (IFPAC). The session detailed challenges facing the industry over the next 10 years and outlined approaches to solving critical scientific and technical hurdles. A full summary of this session is available here as well as a recent BioPharm International news article highlighting the session.
Affiliated Faculty
- Anthony Sinskey, ScD, Faculty Director, CBI; Professor of Biology and Health Sciences and Technology, MIT
- Rajeev Ram, PhD, Director, MIT Center for Integrated Photonic Systems; Associate Director, Research Laboratory of Electronics, MIT; Professor of Electrical Engineering and Computer Science, MIT
For information about BioMAN Working Groups, click here.
Program Director
Dr. Stacy L. Springs, MIT Center for Biomedical Innovation
BioMAN Steering Committee
- Dr. Ali Afnan, Office of Pharmaceutical Science, Center for Drug Evaluation and Research, FDA
- Prof. Charles Cooney, MIT Robert T. Haslam Professor of Chemical Engineering and Faculty Director, Deshpande Center of Technological Innovation
- Dr. Ajaz Hussain, VP Biological Systems Research, PMI
- Dr. Beth Junker, Senior Director of Fermentation Development and Operations, Merck
- Dr. Michael Koplove, VP Biotech Technology and Engineering, Wyeth
- Dr. Ann Lee, VP Process Development, Genentech Inc.
- Dr. Martin Rhiel, Cell and Process R&D, Novartis Pharma AG
- Mr. Johan van Walsem, Senior VP, Engineering, Manufacturing & Operations, Joule Biotechnologies
- Dr. Terri Lynn Vicenzi, Manufacturing Science & Technology, Eli Lilly and Co.
For more information, please contact Stacy Springs at 617-253-3084 or ssprings@mit.edu.
